OTC · Biotechnology

CytoDyn Inc. (CYDY) Stock

$0.19 +0.00% OTC: CYDY Healthcare

CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase.

Valuation

MetricValue
Price$0.19
Market Cap$260.25M
P/E Ratio-5.94
P/B Ratio-2.32
P/S Ratio-43.99
EPS (TTM)$0.00
52-Week High$0.40
52-Week Low$0.19
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE36.98%
ROA-209.73%
ROCE65.89%
Gross Margin0.29%
Operating Margin355.63%
Net Margin655.73%
Debt/Equity-0.26
Current Ratio0.37

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$-6.0M
Operating Profit$-105.0M$-145.0M$-41.0M$-18.0M$11.0M
Net Profit$-174.0M$-211.0M$-80.0M$-50.0M$4.0M
EPS$-0.30$-0.43$-0.10$-0.05$0.00
Op Margin—-54663.2%——-191.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$132.0M$29.0M$11.0M$11.0M$18.0M
Total Liabilities$153.0M$124.0M$121.0M$128.0M$114.0M
Cash$34.0M$4.0M$3.0M$3.0M$12.0M
Borrowings$63.0M$37.0M$35.0M$30.0M$27.0M

Latest News

CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease GlobeNewswire · Jun 11, 2026 CytoDyn to Present at the LD Micro Invitational XVI GlobeNewswire · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-118.0M$-78.0M$-25.0M$-11.0M$-9.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$38.0M$7.0M$3.0M$1.0M$12.0M
Net Cash Flow$20.0M$-30.0M$5.0M$1.0M$2.0M
Free Cash Flow$-118.0M$-78.0M$-25.0M$-11.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA-7.15
FCF Yield-3.46%
Quick Ratio0.37
Interest Coverage-7.09
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held0.01%
Institutions Held0.01%
Institutions Float Held0.01%
Institutional HolderSharesReport Date
Williams Jones Wealth Management, LLC.45,0012026-03-31
Next Capital Management, LLC25,0002026-03-31
Caz Investments LP4,0002026-03-31
Ancora Advisors, LLC9,4882026-03-31
Diversified Trust Company45,7902026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BOVNFBioInvent International AB (publ) $3.29 +0.00% -4.47 $216.40M 0.00%
CLVLFClinuvel Pharmaceuticals Limited $6.37 +0.00% 13.94 $321.12M 0.47%
CLVLYClinuvel Pharmaceuticals Limited $6.83 -2.57% 13.94 $344.42M 0.44%
CMVLFCellectis S.A. $3.47 +12.66% -4.24 $251.93M 0.00%
FGHQFFrontage Holdings Corporation $0.15 +11.11% 44.83 $304.16M 0.00%

About CytoDyn Inc.

CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.

CytoDyn Inc. is headquartered in US.

CytoDyn Inc. (CYDY) stock trades at $0.19 with a market capitalization of $260.25M. The stock is valued at a price-to-earnings (P/E) ratio of -5.94, price-to-book of -2.32, price-to-sales of -43.99. Over the past 52 weeks the stock has ranged between $0.19 and $0.40, and currently trades 52.5% below its 52-week high.

On profitability, CytoDyn Inc. generates a return on equity (ROE) of 36.98% — well above the market average, a sign of a high-quality business, return on capital employed of 65.89%, an operating margin of 355.63%, a net profit margin of 655.73%.

Official website: www.cytodyn.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides